TearClear Appoints Chief Scientific and Innovation Officer

UF startup TearClear, the specialty pharmaceutical company uniquely focused on developing a family of preservative-free topical ophthalmic drugs, announced another big step forward with the appointment of Srini Venkatesh, Ph.D., as Chief Scientific and Innovation Officer. Dr. Venkatesh will be responsible for setting the scientific and clinical strategy for TearClear, as well as overseeing day-to-day research and development operations.

“Srini is a welcome addition to the TearClear executive team, bringing tremendous experience in ophthalmic drug development and expertise in pharmaceutical formulations,” commented Kevin Hershfield, Chief Executive Officer. “This appointment reflects the next stage of our Company’s advancement in bringing to market a family of truly differentiating specialty ophthalmic pharmaceuticals that address unmet patient needs.”

Learn more about TearClear Appoints Chief Scientific and Innovation Officer.